Psilocybin is under clinical development by Silo Pharma and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition ...
Results of a Phase II study demonstrate the effectiveness of EsoCaps’s ESO-101’s in eosinophilic esophagitis, an increasingly recognized, chronic, local immune-mediated esophageal disease. NovaGo ...
INR:4676. rummy mega slot and fly All patients reached clinical endpoints. Positive results of Phase 2a clinical trial of innovative therapy for Clostridi ...